Literature DB >> 8476633

Endothelin in human nasal mucosa.

J Mullol1, B A Chowdhury, M V White, K Ohkubo, R D Rieves, J Baraniuk, J N Hausfeld, J H Shelhamer, M A Kaliner.   

Abstract

Endothelin (ET), a potent vasoconstrictor and bronchoconstrictor peptide synthesized by endothelial and epithelial cells, was examined for its potential functions in human inferior turbinate nasal mucosal tissue by four techniques: (1) immunoreactive ET was localized in the mucosa by immunohistochemistry; (2) receptors for ET were identified by autoradiography employing [125I]ET; (3) ET-1 mRNA was localized by in situ hybridization; and (4) the secretory functions of ET were examined by the release of mucous and serous cell products after the addition of ET to human nasal turbinates in short-term cultures. Specific ET-1-immunoreactive material was found most extensively in small muscular arteries and in serous cells in submucosal glands. ET-1 was also found to a lower extent in the walls of venous sinusoids. [125I]ET-1 binding sites were localized by autoradiography to submucosal glands and to venous sinusoids and small muscular arterioles. mRNA for ET-1 was found most extensively in the venous sinusoids and to a lesser extent in small muscular arteries. In mucosal explant cultures, ET-1 and ET-2 stimulated lactoferrin and mucous glycoprotein release from serous and mucous cells, but ET-3 was inactive. The observations indicate that in the human nasal mucosa, ET is present in the vascular endothelium and the serous cells in submucosal glands and acts on glandular ET receptors to induce both serous and mucous cell secretion. It is also likely that ET plays a role in the regulation of vasomotor tone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476633     DOI: 10.1165/ajrcmb/8.4.393

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

Review 1.  Immunity, infection, and nasal disease.

Authors:  S H Yoshida; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  1998 Spring-Summer       Impact factor: 8.667

2.  Topical administration of hyaluronic acid in children with recurrent or chronic middle ear inflammations.

Authors:  Sara Torretta; Paola Marchisio; Vittorio Rinaldi; Michele Gaffuri; Carla Pascariello; Lorenzo Drago; Elena Baggi; Lorenzo Pignataro
Journal:  Int J Immunopathol Pharmacol       Date:  2016-06-24       Impact factor: 3.219

3.  Receptors for endothelin-1 in asthmatic human peripheral lung.

Authors:  P G Knott; A C D'Aprile; P J Henry; D W Hay; R G Goldie
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 4.  Viral rhinitis.

Authors:  D A Gentile; D P Skoner
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.806

5.  Endoscopic and clinical benefits of hyaluronic acid in children with chronic adenoiditis and middle ear disease.

Authors:  S Torretta; P Marchisio; V Rinaldi; D Carioli; E Nazzari; L Pignataro
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-01       Impact factor: 2.503

6.  Potentiation by endothelin-1 of cholinergic nerve-mediated contractions in mouse trachea via activation of ETB receptors.

Authors:  P J Henry; R G Goldie
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 7.  Mechanisms of allergic rhinitis.

Authors:  J N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.